Nottingham Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Nottingham Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,355	Closed	-$212K	–	144
2022 Q1	$212K	Hold	2,355	–	–	0.03%	133
2021 Q4	$264K	Hold	2,355	–	–	0.03%	123
2021 Q3	$296K	Hold	2,355	–	–	0.03%	115
2021 Q2	$319K	Sell	2,355 -600	-20%	-$78.9K	0.04%	112
2021 Q1	$401K	Sell	2,955 -290	-9%	-$43.4K	0.05%	106
2020 Q4	$457K	Buy	3,245 +455	+16%	+$58.3K	0.07%	92
2020 Q3	$311K	Buy	+2,790	New	+$313K	0.04%	106

Other funds holding XBI

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Nottingham Advisors's XBI Position: Q2 2022 in Review

Nottingham Advisors sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2022, closing a stake of 2,355 shares — an estimated $212K sold.

Nottingham Advisors first reported a position in XBI in Q3 2020 and held it in 7 quarters. The position peaked at $457K in Q4 2020. 706 funds tracked by Wall St. Rank hold XBI as of Q2 2022.

Nottingham Advisors reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2022 after selling out during the quarter.
Nottingham Advisors sold 2,355 State Street SPDR S&P Biotech ETF shares in Q2 2022, an estimated $212K.
Nottingham Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q3 2020 and held it in 7 quarters.
Nottingham Advisors's State Street SPDR S&P Biotech ETF position peaked at $457K in Q4 2020.
706 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2022.

Based on Nottingham Advisors's 13F filing for Q2 2022, filed 10 Aug 2022.